Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03391765 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT03391765 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 142 participants.
The verdict
NCT03391765, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).
Interventions
- DRUG ABBV-8E12
- DRUG Placebo solution for IV infusion on Day 15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2019-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03391765
The ClinicalTrials.gov registry entry for NCT03391765 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-8E12 is the first listed.
NCT03391765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03391765 about?
NCT03391765 is a clinical study titled "An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)". The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).
What is the current status of trial NCT03391765?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2018-01-24. Estimated completion is 2019-12-13.
What interventions are being tested in trial NCT03391765?
The interventions under investigation include: ABBV-8E12 (DRUG), Placebo solution for IV infusion on Day 15 (DRUG).
Who is sponsoring clinical trial NCT03391765?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.